Pfizer Inc.’s (PFE) first-quarter results were in-line with the company’s expectations, underlining its continued confidence in achieving 7% to 9% operational revenue growth for the fiscal year 2023. Moreover, the company expects the majority of this growth to occur in the second half of this year, driven by its expected near-term product launches.
Given its solid fundamentals, attractive dividend, and promising growth outlook, investors could consider scooping up shares of PFE for potential gains. In this article, I will discuss several reasons why I am extremely bullish on PFE.
